Fenretinide differentially modulates the levels of long- and very long-chain ceramides by downregulating Cers5 enzyme: evidence from bench to bedside
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu klinické zkoušky, časopisecké články, práce podpořená grantem
PubMed
28695226
DOI
10.1007/s00109-017-1564-y
PII: 10.1007/s00109-017-1564-y
Knihovny.cz E-zdroje
- Klíčová slova
- Ceramides, Cystic fibrosis, Fenretinide,
- MeSH
- aktivace transkripce účinky léků MeSH
- buněčné linie MeSH
- ceramidy analýza krev metabolismus MeSH
- cystická fibróza krev farmakoterapie metabolismus MeSH
- dospělí MeSH
- down regulace účinky léků MeSH
- fenretinid terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- modely nemocí na zvířatech MeSH
- myši inbrední C57BL MeSH
- myši knockoutované MeSH
- PPAR gama agonisté MeSH
- sfingosin-N-acyltransferasa antagonisté a inhibitory genetika metabolismus MeSH
- zvířata MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- práce podpořená grantem MeSH
- Názvy látek
- ceramidy MeSH
- CERS5 protein, human MeSH Prohlížeč
- fenretinid MeSH
- PPAR gama MeSH
- sfingosin-N-acyltransferasa MeSH
UNLABELLED: Cystic fibrosis is the most common genetic disease, in which symptoms may be alleviated but not fully eliminated. Ceramides have long been implicated in the inflammatory etiology of cystic fibrosis, with contradicting reports with regards to their role. Recently, significant biological and biophysical differences have been observed between long- and very long-chain ceramides. This work reveals that long-chain ceramides are upregulated whereas very long-chain ceramides are downregulated in cell lines, mouse animal model, and patients with cystic fibrosis, compared with their controls. Treatment with fenretinide decreases the levels of long-chain ceramides and increases the levels of very long-chain ceramides. Our results show that restoration of cystic fibrosis conductance regulator (CFTR) expression is associated with normalization of aberrant levels of specific ceramides. This demonstrates for the first time a correlation between CFTR protein expression and regulation of specific ceramide levels. Furthermore, using cystic fibrosis lung epithelial cell lines, we demonstrate that this effect can be attributed to the transcriptional downregulation of ceramide synthase 5 (Cers5) enzyme. We also discovered a partial synergism between fenretinide and zinc (Zn2+), which deficiency has been reported in patients with cystic fibrosis. Overall, in addition to having direct translational application, we believe that our findings contribute to the understanding of ceramide metabolism in cystic fibrosis, as well as other inflammatory diseases where imbalances of ceramides have also been observed. KEY MESSAGES: Long- and very long-chain ceramides (LCCs and VLCCs) are biochemically distinct. LCCs are upregulated whereas VLCCs are downregulated in cystic fibrosis. Fenretinide downregulates the levels of LCCs and upregulates the levels of VLCCs. Fenretinide changes the balance of LCCs and VLCCs by downregulating Cers5 enzyme. Fenretinide and zinc ions cooperate in the modulation of ceramide levels.
Academic Neuroscience Centre King's College London London UK
Department of Human Genetics McGill University Montreal Quebec Canada
Department of Immunology Central University of Venezuela Caracas Bolivarian Republic of Venezuela
Department of Physiology McGill University Montreal Quebec Canada
McGill University Health Center 1001 Decarie Boulevard Room EM 23242 Montreal Quebec H4A 3J1 Canada
Zobrazit více v PubMed
J Cell Physiol. 2004 Aug;200(2):235-44 PubMed
Nat Rev Genet. 2015 Jan;16(1):45-56 PubMed
Pediatr Pulmonol. 2008 Mar;43(3):281-7 PubMed
Am J Respir Cell Mol Biol. 2009 Jul;41(1):100-6 PubMed
Int J Biochem Cell Biol. 2012 Apr;44(4):620-8 PubMed
Transl Res. 2016 Feb;168:40-49 PubMed
Am J Respir Cell Mol Biol. 2008 Jan;38(1):47-56 PubMed
Otolaryngol Head Neck Surg. 2005 Nov;133(5):695-701 PubMed
J Nutr. 2003 Oct;133(10 ):3058-64 PubMed
Nat Med. 2003 Mar;9(3):322-30 PubMed
Nat Med. 2008 Apr;14(4):382-91 PubMed
J Lipid Res. 2012 Dec;53(12):2755-66 PubMed
Clin Transl Oncol. 2009 Apr;11(4):243-9 PubMed
Am J Physiol Lung Cell Mol Physiol. 2008 Aug;295(2):L303-13 PubMed
Prog Lipid Res. 2012 Jan;51(1):50-62 PubMed
J Biol Chem. 2012 Jun 15;287(25):21025-33 PubMed
Pediatr Res. 2014 Jun;75(6):762-6 PubMed
J Physiol. 2005 Dec 1;569(Pt 2):601-15 PubMed
J Biol Chem. 2001 Jun 8;276(23):20589-96 PubMed
Am J Respir Cell Mol Biol. 1993 May;8(5):522-9 PubMed
Drug Des Devel Ther. 2016 Nov 01;10 :3591-3597 PubMed
Histochem Cell Biol. 2013 Nov;140(5):533-47 PubMed
IUBMB Life. 2010 May;62(5):347-56 PubMed
Biochim Biophys Acta. 2005 Dec 30;1746(3):284-94 PubMed
Trends Mol Med. 2012 May;18(5):283-91 PubMed
J Lab Clin Med. 1957 Jul;50(1):152-7 PubMed
Ann Nutr Metab. 2008;52(2):152-6 PubMed
Mol Med. 2015 Apr 21;21:257-75 PubMed
Biometals. 2001 Sep-Dec;14(3-4):367-83 PubMed
Am J Respir Crit Care Med. 2010 Aug 1;182(3):369-75 PubMed
EMBO Mol Med. 2014 Aug 01;6(9):1205-14 PubMed
Nat Med. 2002 Jun;8(6):588-93 PubMed
Nat Med. 2010 Mar;16(3):313-8 PubMed
J Invest Dermatol. 2012 Feb;132(2):476-9 PubMed
Anal Biochem. 2013 Oct 15;441(2):182-4 PubMed
J Immunol. 2004 Jan 1;172(1):418-25 PubMed
J Biol Chem. 2001 Jun 29;276(26):23954-61 PubMed
J Phys Chem B. 2014 Sep 4;118(35):10460-70 PubMed
J Biol Chem. 1957 May;226(1):497-509 PubMed
PLoS One. 2013 May 14;8(5):e62968 PubMed
N Engl J Med. 2007 Jun 14;356(24):2457-71 PubMed
Hum Mutat. 2011 Nov;32(11):1197-203 PubMed
J Nutr. 2004 Jul;134(7):1711-5 PubMed
J Invest Dermatol. 1991 Apr;96(4):523-6 PubMed
The role of essential fatty acids in cystic fibrosis and normalizing effect of fenretinide